SavedAdd your journal

Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 12

The safety of alpha fetoprotein in diagnosis of hepatocellular carcinoma in patients with type 2 diabetes mellitus

Tolga ŞAHİN
Erdem KOÇAK
Pages
2961–2965
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum AFP levels were compared with age, BMI, HgbA1c, fasting plasmaglucose level (FPG), serum insulin level and insulin resistance (HOMA-IR).Results: AFP levels were higher in T2DM + HCC group patients according to healthy control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Diabetes mellitus is closely associated with many types of cancer including hepatocellular carcinoma (HCC).
📊
Key Findings & Data:Alpha feto proteinis still used as a biomarker for HCC worldwide but relation between type 2 diabetes mellitus (T2DM) and AFP is unclear.
💡
Conclusion & Impact:Serum AFP levels were compared with age, BMI, HgbA1c, fasting plasmaglucose level (FPG), serum insulin level and insulin resistance (HOMA-IR).Results: AFP levels were higher in T2DM + HCC group patients according to healthy control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Diabetes mellitus is closely associated with many types of cancer including hepatocellular carcinoma (HCC). Alpha feto proteinis still used as a biomarker for HCC worldwide but relation between type 2 diabetes mellitus (T2DM) and AFP is unclear. We aimed toinvestigate relations between AFP, T2DM and metabolic markers in this study.Material and Methods: 208 HCC patients were enrolled to study. 50 patients had T2DM (T2DM+HCC) and 158 patients were nondiabetic (NDM+HCC). 50 healthy people enrolled to the study as control group. Serum AFP levels were compared between healthycontrol group, T2DM+HCC group and NDM+HCC group. Serum AFP levels were compared with age, BMI, HgbA1c, fasting plasmaglucose level (FPG), serum insulin level and insulin resistance (HOMA-IR).Results: AFP levels were higher in T2DM + HCC group patients according to healthy control group (p

🔖

Cite This Article

ŞAHİN, T., KOÇAK, E. (2022). The safety of alpha fetoprotein in diagnosis of hepatocellular carcinoma in patients with type 2 diabetes mellitus. Annals of Medical Research, Cilt: 26 - Sayı: 12, 2961–2965. https://ajindex.com/articles/447191

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:359-86
  2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27
  3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42:206-14
  4. Group IDFDA. Update of mortality attributable to diabetes for the IDF diabetes atlas: estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5
  5. Ali Kamkar MM, Ahmad R, Alsmadi O, et al. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord 2014;22:1-57
  6. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80
  7. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38
  8. Møller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30:344-50
  9. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21
  10. Vora SR, Zheng H, Stadler ZK, et al. Serum alphafetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14:717-25
  11. Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res 2013;19:3944-54
  12. Liu CY, Feng GS. NCOA5, a molecular link between type 2 diabetes and liver cancer, Hepatobiliary Surg Nutr 2014;3:106-8
  13. Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer 2005;92:2076-83
  14. Chen L, Li H, Gu L, et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies, Medicine Baltim 2015;94:1055
  15. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review, World J. Gastroenterol 2015; 21:6026-31
  16. Chen HF, Liu MD, Chen P, et al. Risks of breast and endometrial cancer in women with diabetes: A population-based cohort study, PLoS ONE